AVMA Position on Cannabinoids in Pets — What It Means

The American Veterinary Medical Association issued a formal policy statement in 2018 that fundamentally rejects veterinary cannabis use until FDA-approved cannabinoid products exist with documented safety profiles across species. This isn't a moral stance. It's a regulatory position rooted in the fact that no hemp-derived pet product has passed FDA drug approval standards, meaning veterinarians cannot legally prescribe cannabinoids and manufacturers cannot make medical claims without risking federal enforcement. The AVMA position on cannabinoids in pets creates a legal gray zone where products exist in massive retail volume but cannot be recommended by licensed veterinarians under their professional liability insurance.

We've watched this regulatory gap widen every year since 2018. Pet owners are buying cannabinoid products at scale. The pet CBD market exceeded $400 million in 2025 according to Brightfield Group's market analysis. But veterinarians are professionally prohibited from guiding that use. The disconnect runs on unresolved federal scheduling conflicts between the 2018 Farm Bill (which legalized hemp) and FDA drug approval pathways (which still classify cannabinoids as investigational compounds requiring clinical trials).

What is the AVMA's official position on cannabinoid use in pets?

The AVMA opposes cannabis administration to animals until clinical trials establish species-specific safety profiles, dosing protocols, and drug interaction data through FDA-approved pathways. Their 2018 resolution states veterinarians should not recommend cannabinoid products lacking regulatory approval, should educate clients on unknown risks, and should advocate for research funding to close the evidence gap. The position does not ban discussion. It bans recommendation pending rigorous scientific validation.

The AVMA position on cannabinoids in pets doesn't dismiss therapeutic potential. It rejects therapeutic claims without controlled evidence. The association acknowledges anecdotal reports of benefit but argues anecdotes cannot substitute for pharmacokinetic studies, toxicity thresholds, and adverse event tracking systems required for FDA drug approval. The practical result: veterinarians can acknowledge a client uses CBD for their pet but cannot advise dosage, frequency, or product selection without violating professional standards.

Why the AVMA Opposes Unregulated Cannabinoid Use

The core objection centres on liability exposure and unknown toxicity parameters. Unlike human cannabis use. Where adult consumers assume their own risk. Pet cannabinoid administration involves a third party (the owner) dosing a patient (the animal) who cannot report side effects. The AVMA argues this dynamic requires pharmaceutical-grade safety standards, not supplement-grade voluntary compliance. Three specific regulatory failures drive their opposition: lack of species-specific pharmacokinetic data, absence of standardised concentration testing, and zero post-market adverse event surveillance infrastructure.

No peer-reviewed study has established safe CBD dosing ranges across breeds, life stages, or concurrent medication profiles in companion animals. A 2019 Colorado State University trial found dogs metabolise CBD differently than humans. With longer half-lives and higher liver enzyme elevations at therapeutic doses. But the study involved only 30 dogs over 12 weeks. The AVMA position on cannabinoids in pets reflects the fact that extrapolating human dosing to animals without species-specific trials has historically caused severe toxicity events (see: ibuprofen, xylitol, grapes). Veterinarians operate under a 'first, do no harm' standard that conflicts with recommending compounds lacking established safety margins.

Veterinary licensing boards in 46 states explicitly prohibit veterinarians from prescribing or recommending cannabis products as of 2026, according to the American Association of Veterinary State Boards. Violations trigger professional discipline ranging from censure to license suspension. The regulatory constraint isn't theoretical. Multiple veterinarians faced board action between 2019 and 2023 for discussing CBD products with clients, even when avoiding explicit medical recommendations.

What the Research Gap Means for Pet Owners

The absence of FDA-approved cannabinoid drugs for animals creates a product landscape with zero quality control enforcement beyond voluntary third-party testing. Unlike human CBD supplements. Which face FTC truth-in-advertising rules. Pet products occupy a regulatory no-man's-land where label claims face minimal scrutiny. A 2021 study published in Frontiers in Veterinary Science tested 29 commercially available pet CBD products and found 9 contained less than 50% of the labelled CBD concentration, 6 contained THC levels exceeding legal limits, and 4 contained heavy metal contaminants above safety thresholds.

This quality variance explains why the AVMA position on cannabinoids in pets emphasises the lack of regulatory oversight as a primary safety concern. Without FDA Good Manufacturing Practice requirements, batch-to-batch consistency cannot be guaranteed. The same product purchased three months apart may deliver radically different cannabinoid concentrations. Creating unpredictable dosing that ranges from subtherapeutic to toxic. Veterinarians cannot ethically recommend products with that level of manufacturing uncertainty.

Our team has reviewed hundreds of third-party Certificate of Analysis reports from pet cannabinoid manufacturers. The pattern is consistent: brands making medical claims ('reduces arthritis pain', 'controls seizures') rarely provide batch-specific testing data. Brands avoiding medical claims and publishing full-panel COAs (cannabinoid potency, pesticide residue, heavy metals, microbial contamination) for every batch represent less than 15% of the retail market. That quality gap is the operational reality behind the AVMA's regulatory stance.

The Veterinarian Liability Problem

Veterinarians face professional liability exposure from two directions simultaneously. Recommending cannabinoid products without FDA approval violates state veterinary practice acts and risks malpractice claims if adverse events occur. But failing to discuss cannabinoids when clients ask creates a communication gap that drives owners toward unvetted online sources with zero veterinary supervision. The AVMA position on cannabinoids in pets attempts to resolve this tension by encouraging honest client education about unknowns while maintaining that formal recommendations require regulatory approval.

Malpractice insurers explicitly exclude cannabis-related claims from standard veterinary liability policies. A veterinarian who recommends a CBD product. Even with disclaimers. May face uncovered liability if that product causes hepatotoxicity, drug interactions, or acute toxicity requiring emergency treatment. The financial risk is compounded by the fact that adverse event reporting for pet cannabinoid products is voluntary and untracked, meaning no baseline toxicity data exists to defend clinical decision-making in court.

This liability dynamic explains why veterinarians often respond to CBD questions with 'I cannot legally discuss that' rather than engaging the topic substantively. The legal framework punishes open discussion more severely than silence, creating an information vacuum that drives pet owners toward unregulated online communities rather than professional guidance.

AVMA Position on Cannabinoids in Pets: Product Comparison

Key Takeaways

• The AVMA's 2018 resolution opposes cannabinoid use in animals until FDA-approved products with species-specific safety data become available through controlled clinical trials.
• Veterinarians in 46 states face professional discipline for recommending cannabis products under current veterinary practice acts, creating a regulatory environment where discussion is legally constrained.
• A 2021 study testing 29 commercial pet CBD products found 31% contained less than half the labelled CBD concentration and 21% contained illegal THC levels or heavy metal contamination.
• No peer-reviewed research has established safe CBD dosing ranges across dog breeds, cat populations, or animals on concurrent medications. The evidence gap the AVMA cites as the core safety concern.
• Pet owners spend over $400 million annually on cannabinoid products that veterinarians cannot legally recommend, prescribe, or dose under professional liability insurance coverage.
• The regulatory conflict stems from the 2018 Farm Bill legalising hemp while FDA drug approval pathways still classify cannabinoids as investigational compounds requiring clinical trials before veterinary use.

What If: AVMA Position Scenarios

What If My Veterinarian Refuses to Discuss CBD for My Pet?

Your veterinarian likely operates under a state practice act that prohibits cannabis discussions without triggering professional liability exposure. Ask explicitly whether they can provide general information about cannabinoid pharmacology and known risks without making product recommendations. Most can engage at that educational level. If they decline entirely, request referral to a veterinarian in a state with more permissive cannabis consultation rules (California, Colorado, Oregon allow discussions with informed consent documentation).

What If I'm Already Giving My Pet CBD and Want Veterinary Guidance?

Inform your veterinarian during every visit. Disclosure protects you from drug interaction risks and allows monitoring for liver enzyme elevations. Bring the product bottle and third-party Certificate of Analysis if available. Most veterinarians will document cannabinoid use in the medical record and adjust other medications accordingly even if they cannot advise dosing. The AVMA position on cannabinoids in pets does not prohibit veterinarians from acknowledging client choices. It prohibits active recommendation.

What If My State Legalises Veterinary Cannabis Prescribing?

As of 2026, only California, Colorado, and Nevada have passed legislation allowing veterinarians to discuss cannabis with clients under specific informed consent protocols. Even in those states, veterinarians cannot prescribe cannabinoids. They can only discuss them and document use without facing automatic board discipline. Full prescribing authority requires FDA drug approval, which overrides state law. If your state passes similar legislation, expect veterinarians to provide educational resources and harm reduction guidance but not product-specific recommendations until FDA approval occurs.

The Blunt Truth About Veterinary Cannabis Regulation

Here's the honest answer: the AVMA position on cannabinoids in pets reflects a regulatory system that has not caught up with market reality. Pet owners are administering cannabinoids at massive scale without veterinary guidance because federal drug approval timelines move in decades while consumer demand moves in quarters. The association's stance is scientifically defensible. You cannot recommend a compound without toxicity data. But it creates a care gap where millions of pets receive unsupervised cannabinoid dosing with zero adverse event tracking.

The bottleneck is economic, not scientific. FDA approval for a single cannabinoid drug requires $50–$100 million in clinical trials across multiple species, life stages, and indication types. No pharmaceutical company has committed that capital to veterinary cannabinoid research because the existing unregulated market already captures consumer demand without regulatory investment. The result: pet cannabinoid products will likely remain in regulatory limbo until either a major adverse event forces FDA intervention or a well-funded pharmaceutical company sees profit incentive in controlled trials.

For pet owners using cannabinoid products now, this means operating without the safety infrastructure veterinary medicine relies on for every other therapeutic compound. We've seen this pattern with other supplement categories. Glucosamine, probiotics, omega-3s all spent years in regulatory gray zones before research volume caught up. The difference: those compounds had lower acute toxicity risk than cannabinoids, which interact with liver enzymes and multiple drug metabolism pathways. The AVMA's position is conservative by necessity because the downside risk of widespread unregulated use isn't theoretical.

Our experience with clients in this space consistently shows the same tension. Pet owners see anecdotal improvement and want to continue use. Veterinarians see liability exposure and unknown long-term risks. Both perspectives are valid within their own frameworks. The resolution requires either FDA approval that provides veterinarians with defensible clinical guidelines, or state-level legislation that shields veterinarians from board discipline when providing cannabinoid guidance with informed consent protocols. Until one of those regulatory shifts occurs, the disconnect remains unresolved. And pet owners make decisions without the professional guidance the veterinary system is designed to provide.

If you're navigating this regulatory gap and want hemp products backed by rigorous third-party testing, our Pure Pet Harmony CBD Tincture publishes batch-specific Certificates of Analysis for every production run. The product cannot replace veterinary advice. That's the regulatory reality the AVMA position creates. But it represents manufacturing transparency that most pet cannabinoid products don't provide. Informed decision-making starts with knowing exactly what's in the bottle, even when regulatory frameworks haven't established what should be in the bottle.